EnzoBiochem Inc. (ENZ)
Medical conditions and diseases are now being detected more accurately and quickly due to the advancement of biotechnology based tools, an example of the benefits biotechnology has brought us, and one which most people will be able to relate to, is the home pregnancy testing kit.

The new generation of home testing kits is able to provide results which are more accurate and are able to be used much earlier than the ones a few years ago.

Illnesses such as strep throat and other infectious diseases are now diagnosed within minutes enabling treatment to begin at a much earlier time where previous tests could take a few days.

Without biotechnology, a new simpler blood test couldn't have been developed which allows us to measure the amount of "bad" cholesterol in the blood, before this conventional methods required separate blood tests which took longer to obtain the results and were much more costly.

EnzoBiochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since ENZ was founded in 1976, their strategic focus has been on the development of enabling technologies in the life sciences field.

EnzoBiochem Inc. recently announced that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.

The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D'Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.

Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary's operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo's presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.

For more information please visit: www.enzo.com

***********************

Cleantech Transit, Inc. (CLNO)

Cleantech Transit, Inc. is in the business of producing and conserving power. Cleantech Transit produces and sells clean electricity globally, with a focus on sustainable energies using renewable resources such as Geothermal, Solar and Wind. Cleantech Transit's goal is to use innovative technologies to reduce electricity consumption and dependence on carbon based energy. Cleantech Transit, Inc. was founded in 2006 and is based in Scottsdale, Arizona.

Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company's ability to earn in 25% of the 500KW Merced Project.

The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.









Read the full article and the disclaimer atennyotcstock.com/?p=17278